BridgeBio is significantly boosted the development of a novel therapy for cardiac amyloidosis, employing Attruby. Preliminary trial results indicates significant improvements for patients diagnosed with a serious https://attrcm060308.blogs-service.com/73278076/firm-progresses-cardiac-amyloidosis-treatment-through-the-therapy